Metabolic dysfunction-associated steatohepatitis

1. Dasatinib + quercetin decreases metabolic dysfunction-associated steatohepatitis in humans (-1.43 ± 1.22 versus -0.39 ± 0.77).

   Human trialfibrotic MASHliverdasatinib 100 mg per day plus quercetin 1,000 mg per daythree consecutive days per week over 3 weeks, repeated across three 7-week cycles

   Dasatinib and quercetin reduce liver fibrosis in a phase-2 MASH trial · Nature metabolism · 1 Oct 2026

Dasatinib + quercetin →